Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance

Accurate identification of breast cancer patients most likely to benefit from adjuvant systemic therapies is crucial. Better understanding of differences between methods can lead to an improved ER, PgR, and HER-2 assessment. The purpose of this preplanned translational research is to investigate the...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Breast Cancer Res Treat
Autori principali: Viale, Giuseppe, Slaets, Leen, de Snoo, Femke A., Bogaerts, Jan, Russo, Leila, van’t Veer, Laura, Rutgers, Emiel J. T., Piccart-Gebhart, Martine J., Stork-Sloots, Lisette, Dell’Orto, Patrizia, Glas, Annuska M., Cardoso, Fatima
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer US 2016
Soggetti:
Clinical Trial
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4764628/
https://ncbi.nlm.nih.gov/pubmed/26820652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-016-3690-6
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi